-
Article
Open AccessPI3K inhibition circumvents resistance to SHP2 blockade in metastatic triple-negative breast cancer
The protein tyrosine phosphatase SHP2 activates oncogenic pathways downstream of most receptor tyrosine kinases (RTK) and has been implicated in various cancer types, including the highly aggressive subtype of...
-
Article
Open AccessA high-throughput drug screen reveals means to differentiate triple-negative breast cancer
Plasticity delineates cancer subtypes with more or less favourable outcomes. In breast cancer, the subtype triple-negative lacks expression of major differentiation markers, e.g., estrogen receptor α (ERα), an...
-
Article
Glucocorticoids promote breast cancer metastasis
Diversity within or between tumours and metastases (known as intra-patient tumour heterogeneity) that develops during disease progression is a serious hurdle for therapy1–3. Metastasis is the fatal hallmark of ca...
-
Article
Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis
In mouse models of breast cancer, anti-CCL2 therapy—thought to be potentially useful in treating cancer—is shown to accelerate the growth of lung metastases on discontinuation due to a surge of recruitment of ...
